AKEBIA THERAPEUTICS, INC. Business Combination, Consideration Transferred
AKEBIA THERAPEUTICS, INC. (AKBA) reported Business Combination, Consideration Transferred of $527.75 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferred1 · last filed 2022-03-01
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2020-03-31 was $527.75M, a 0.00% change year-over-year.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2019-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2019-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for the quarter ending 2019-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for fiscal 2021 was $527.75M, a 0.00% change from fiscal 2020.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for fiscal 2020 was $527.75M, a 0.00% change from fiscal 2019.
- AKEBIA THERAPEUTICS, INC. business combination, consideration transferred for fiscal 2019 was $527.75M.
| Period end | Business Combination, Consideration Transferred | Business Combination, Consideration Transferred 3 month | Business Combination, Consideration Transferred 6 month | Business Combination, Consideration Transferred 9 month | Business Combination, Consideration Transferred 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $527.75M 10-K · filed 2022-03-01 | ||||
| 2020-12-31 | $527.75M 10-K · filed 2021-02-25 | ||||
| 2020-03-31 | $527.75M 10-Q · filed 2020-05-05 | $527.75M derived: sum of 2 quarters · filed 2020-05-05 | $527.75M derived: sum of 3 quarters · filed 2020-05-05 | $527.75M derived: sum of 4 quarters · filed 2020-05-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $0.00 derived: sum of 3 quarters · filed 2020-03-12 | $527.75M 10-K · filed 2020-03-12 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $527.75M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $527.75M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $527.75M 10-Q · filed 2019-05-09 | ||||
| 2018-12-12 | $527.75M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |